Eliminating the Public Health Problem of Hepatitis B and C in the United States Phase One Report (2016) / Chapter Skim
Currently Skimming:
4 Conclusion
4 Conclusion
Pages 135-138
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 135... ...
. The United States has an opportunity and a responsibility to be part of the global action against hepatitis B and C
|
From page 136... ...
. Competition from other products has brought the price down, but curing a chronically infected HCV patient in the United States still costs between $54,000 and $168,000 (Bickerstaff, 2015; Loria, 2016)
|
From page 137... ...
It is also possible that limitations in disease surveillance, screening, treatment, vaccination, and research are all consequences of a more basic problem. Viral hepatitis is not a public priority in the United States.
|
From page 138... ...
2015. Cost-effectiveness and budget impact of hepatitis V virus treatment with sofosbuvir and ledipasvir in the United States.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.